Description du projet
Développement de la fabrication de cardiomyocytes à base de cellules souches pour soigner l’insuffisance cardiaque
Exprimées à la surface des cellules, les protéines de l’antigène leucocytaire humain (HLA) permettent au système immunitaire de reconnaître les cellules étrangères. Les cellules provenant de donneurs homozygotes HLA peuvent être utilisées à des fins thérapeutiques chez des patients présentant au moins un type de HLA identique. Le projet HEAL, financé par l’UE, vise à perfectionner la technologie des cardiomyocytes dérivés de cellules souches homozygotes HLA en faveur d’une thérapie réparatrice de l’insuffisance cardiaque affichant une immunosuppression minimale. Ses objectifs comprennent le développement d’un algorithme d’intelligence artificielle qui prévoit la réponse immunitaire des individus, l’optimisation de l’administration des produits cellulaires et l’évaluation du risque d’arythmie induite par la greffe dans un modèle animal. Le projet vise à obtenir l’homologation de ses produits et de ses tests et protocoles connexes afin de réaliser la première étude chez l’homme visant à soigner l’insuffisance cardiaque grâce aux cellules.
Objectif
HEAL will focus on general bottlenecks to induced pluripotent stem cell therapies with a particular focus on heart failure, which remains a major cause of morbidity and mortality with very few treatment options.
HLA-homozygous cell line derived cardiomyocyte aggregates offer the prospect of a restorative heart therapy applicable to large patient populations and to overcome economic barriers associated with autologous approaches. By developing solutions for their mass-production and cryopreservation we will enable allogeneic treatment with minimum requirements for immunosuppression.
Assays for assessment of immunogenicity will provide data for the development of an artificial intelligence powered algorithm to predict recipients's immune responses for personalised design of immunosuppression protocols.
A potency assay to assure product effectiveness will be developed together with assays of tumorigenicity in vitro and in vivo that meet and exceed current regulatory requirements. A genetic integrity pipeline defining the most sensitive assays for rigorous assessment will be developed and a rescue tool in the form of a biallelic suicide gene for programmed cell death will add to the safety toolbox for the therapy.
Optimisation of cell-product administration in terms of retention and engraftment, including catheter-based delivery as minimally invasive alternative to surgical application, and assessment of risks of graft-induced arrhythmia will be determined in a pig model.
Early dialogues, via established links, to the regulatory authorities will ensure proper development according to GMP requirements.
Freedom to operate and licensing strategies with a health technology and infrastructure assessment of European centres will set the scene for approval of the cell product and related assays and protocols for storage and distribution required to progress towards a first in man study of cell-based heart repair.
Champ scientifique
- natural sciencescomputer and information sciencesartificial intelligence
- medical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmia
- social sciencessociologydemographymortality
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
Mots‑clés
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
30625 Hannover
Allemagne